<DOC>
	<DOCNO>NCT01480596</DOCNO>
	<brief_summary>Study BEL115123 randomize , placebo-controlled , double-blind , multinational study belimumab ( 10 mg/kg ) investigate efficacy safety belimumab subject MG . The study enroll male female outpatient ( &gt; equal 18 year age ) diagnosis MG 1 ) acetylcholine receptor ( AChR ) antibody positive muscle specific kinase ( MuSK ) antibody positive , 2 ) current standard care therapy , 3 ) continue exhibit sign MG . The study include 3 phase : 4 week screening period , 24 week treatment period , 12 week follow-up period . IP administer intravenously Days 0 , 14 , 28 every 28 day include Week 20 . At Week 24 , primary outcome obtain . Follow evaluation conduct Weeks 28 , 32 36 subject . The primary objective study assess efficacy belimumab evaluate change quantitative myasthenia gravis ( QMG ) score .</brief_summary>
	<brief_title>The Evaluation Belimumab Myasthenia Gravis ( MG )</brief_title>
	<detailed_description />
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>18 year old , life expectancy great 1 year . MG class II IVa inclusive . Acetylcholine receptor ( AChR ) muscle specific kinase ( MuSK ) antibody positive . Stable dose ( define dose change ) exceed maximum dos give Section 5.6.1 follow therapy ( y ) prior screen : Cholinesterase inhibitor ( pyridostigmine equivalent ) least 2 week prior screen immunosuppressant ; Cholinesterase inhibitor ( pyridostigmine equivalent ) least 2 week prior screen and/or one following : prednisone ( 40 mg/day equivalent ) least 1 month prior screen ; azathioprine least 6 month prior screen ; mycophenolate least 6 month prior screen , cyclosporine least 3 month prior screen ; Cholinesterase inhibitor ( pyridostigmine equivalent ) least 2 week prior screen and/or prednisone ( 20 mg/day equivalent ) least 1 month prior screen one following : azathioprine least 6 month prior screen , mycophenolate least 6 month prior screen , cyclosporine least 3 month prior screen Quantitative Myasthenia Gravis ( QMG ) score 8 great , least 4 point derive sign ocular A female subject eligible participate : Of nonchildbearing potential ; Of childbearing potential NOT pregnant nursing , negative serum pregnancy test screening , agree one following : Complete abstinence penilevaginal intercourse , female 's preferred usual lifestyle , period consent study 16 week last dose investigational product ; Consistent correct use one follow acceptable method birth control period consent study 16 week last dose investigational product : Oral contraceptive ( either combine progesterone ) , Injectable progesterone , Implants etonogestrel levonorgestrel , Estrogenic vaginal ring , Percutaneous contraceptive patch , Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year , Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study ; male must sole partner subject , Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) . Capable give write informed consent , include compliance requirement restriction list consent form . Single QTc le 450 msec ; QTc le 480 msec subject Bundle Branch Block . AST ALT le 2xULN ; alkaline phosphatase bilirubin less = 1.5xULN ( isolate bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % ) . Participated clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) prior screen plan take investigational drug plan duration study participation ( 6 month last dose study drug ) . Presence previous history thymoma . Thymectomy within 12 month Clinically significant ( opinion investigator ) abnormal laboratory value . Pregnant female determine positive ( serum ) hCG test screen prior dosing , lactate female plan become pregnant within 16 week last dose investigational product . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . May require ( opinion investigator ) treatment IVIg and/or plasmapheresis 24 week treatment period . Have receive IVIg and/or plasmapheresis within 90 day prior screen . Have receive biopharmaceutical agent ( except IVIg describe exclusion criterion # 8 ) 364 day prior screen . Have receive treatment B cell target therapy ( e.g. , rituximab , belimumab ) , time . Have receive live vaccine within 30 day study Day 0 ( baseline ) . Have receive cyclophosphamide immunosuppressive agent apart one allow inclusion criterion # 4 , within past 6 month . Have another medical condition require treatment steroid immunosuppressive agent . Hospitalization due infection use parenteral antibacterial , antifungal antiviral agent within 60 day prior screen ; history recurrent chronic infection , currently active systemic infection . Have history malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Have history major organ transplant ( eg , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Have historically positive test test positive screening HIV1 , hepatitis B surface antigen hepatitis C antibody . Have IgG Grade 3 great deficiency ( less = 400mg/dL ) . Have IgA deficiency ( IgA less 10mg/dL ) . Have history anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . Has progressive medical , neurological psychological condition situation , investigator 's judgment , likely cause subject unable unwilling participate study procedure , complete schedule assessment , precludes accurate assessment . Is currently abuse drug alcohol history abuse last 12 month . Subjects evidence serious suicide risk include history suicidal behavior last 6 month and/or suicidal ideation type 4 5 CSSRS last 2 month investigator 's judgment , pose significant suicide risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>